Format

Send to

Choose Destination
Pharmacogenomics. 2014 Nov;15(14):1763-1769.

PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.

Author information

1
Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, 08035, Spain.

Abstract

AIM:

Variation at PDE3A-SLCO1C1 locus has been recently associated with the response to anti-TNF therapy in rheumatoid arthritis. We undertook the present study to determine whether PDE3A-SLCO1C1 is also associated with the response to anti-TNF therapy in psoriatic arthritis.

PATIENTS & METHODS:

Genomic DNA was obtained from 81 psoriatic arthritis patients that had been treated with anti-TNF therapy. PDE3A-SLCO1C1 SNP rs3794271 was genotyped using Taqman realt-time PCR. The clinical response to anti-TNF therapy was measured as the change from baseline in the level of disease activity according to the DAS28 score.

RESULTS:

A significant association between rs3794271 and anti-TNF response in psoriatic arthritis was found (beta = -0.71; p = 0.0036).

CONCLUSION:

PDE3A-SLCO1C1 locus is also associated with response to anti-TNF therapy in psoriatic arthritis. Original submitted 12 May 2014; Revision submitted 18 August 2014.

KEYWORDS:

anti-TNF therapy; genetic marker; psoriatic arthritis; single nucleotide polymorphism; treatment response

PMID:
25493569
DOI:
10.2217/pgs.14.125

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center